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Thoraxcenter, Erasmus Medical CenterBackground Post percutaneous coronary intervention (PCI) fractional flow reserve (FFR) is a significant predictor of
major adverse cardiac events (MACE). The rationale for low post procedural FFR values often remains elusive based on
angiographic findings alone, warranting further assessment using an FFR pullback or additional intravascular imaging. It is
currently unknown if additional interventions intended to improve the PCI, decrease MACE rates.
Study design The FFR REACT trial is a prospective, single-center randomized controlled trial in which 290 patients with
a post PCI FFR b0.90 will be randomized (1:1) to either standard of care (no additional intervention) or intravascular
ultrasound (IVUS)-directed optimization of the FFR (treatment arm). Eligible patients are those treated with angiographically
successful PCI for (un)stable angina or non-ST elevation myocardial infarction (MI). Assuming 45% of patients will have a post
PCI FFR b0.90, approximately 640 patients undergoing PCI will need to be enrolled. Patients with a post PCI FFR ≥ 0.90 will
be enrolled in a prospective registry. The primary end point is defined as a composite of cardiac death, target vessel MI and
clinically driven target vessel revascularisation (target vessel failure) at 1 year. Secondary end points will consist of individual
components of the primary end point, procedural success, stent thrombosis and correlations on clinical outcome, changes in
post PCI Pd/Pa and FFR and IVUS derived dimensions. All patients will be followed for 3 years.
Conclusion The FFR-REACT trial is designed to explore the potential benefit of HD-IVUS-guided PCI optimization in
patients with a post PCI FFR b0.90 (Dutch trial register: NTR6711). (Am Heart J 2019;213:66-72.)Background
Accurate angiographic assessment of the severity and
hemodynamic importance of coronary artery stenosis can
be challenging and proved to be frequently unreliable.1,2
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https://doi.org/10.1016/j.ahj.2019.03.017procedural fractional flow reserve (FFR) in patients
with multivessel coronary artery disease undergoing
percutaneous coronary intervention (PCI) with drug-
eluting stents significantly reduces the rate of the
composite end point of death, nonfatal myocardial
infarction (MI), and repeat revascularization at 1 year as
compared to angiographic guided PCI.3 More recently,
FFR after stenting proved to be a strong and independent
predictor of major adverse cardiac events (MACE) at 1
year.4 A contemporary meta-analysis on the clinical
impact of post PCI FFR values showed that an FFR
b0.90 is associated with an increased risk of target vessel
revascularization (TVR).5
A number of factors might cause a post-PCI pressure
drop over a treated segment including residual disease in
the proximal or distal segment, a geographically
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Volume 213misplaced stent, stent underexpansion, malapposition,
plaque protrusion, edge dissection and plaque shift.6,7
While these findings are not always readily apparent on
coronary angiography alone, high definition (HD) intra-
vascular ultrasound (IVUS) demonstrated to be a power-
ful tool to detect potential causes for low FFR post
stenting. More specifically, these issues proved to be
more frequently present in patients with low as
compared to high post PCI FFR.7 The latter adds to the
substantial body of evidence on the benefit of IVUS-
guided PCI as compared to angiography-guided PCI in
improving long-term outcomes.8,9
While post PCI FFR is at present only rarely performed
in routine clinical practice, an FFR after stenting b0.90
proved to be present in approximately 45% of the
patients.10 Additionally, IVUS was able to detect prob-
lems of intraluminal obstruction in up to 84% of those
cases.7 It is currently unknown if additional interventions
with the intent to optimize post procedure FFR improve
patient outcome.
The rationale and design of the FFR REACT trial was
based on a simple and fast way of measuring post PCI FFR
using a small microcatheter over the previously used
coronary guidewire. Although a substantial body of
evidence exists towards a pressure wire based post PCI
FFR of 0.90 to predict MACE, at the moment no clear cut-
off for post PCI FFR value as measured with a
microcatheter to predict events has been established.4,5
The potential findings and clinical implications of this
study might open the door to a more frequent use of post
PCI physiological assessment with the intention to
further reduce the risk of future MACE with the help of
IVUS.
Study aims
To assess if FFR guided PCI optimization directed by
HD-IVUS in patients with an increased risk for MACE
(post-PCI FFR below 0.90) will improve clinical outcome
and reduce target vessel failure, a composite of cardiac
death, target-vessel myocardial infarction and clinically
driven TVR at 1 year.
Study design and methods
The FFR REACT trial is a prospective, investigator
initiated single-center randomized controlled trial in
which 290 patients with a post PCI FFR b0.90 will be
randomized (1:1) to either standard of care (no additional
intervention, control arm) or IVUS-directed optimization
of the FFR (treatment arm). Eligible patients are those
treated with angiographically successful PCI for stable or
unstable angina or a non-ST elevation myocardial
infarction (MI). Patients with a post PCI FFR ≥0.90 will
be enrolled in a prospective registry. All patients will be
included in the Erasmus Medical Center (MC), the
Netherlands, and followed for up to 3 years after PCI.The study flowchart is depicted in Figure 1. The study
protocol was approved by our local ethical committee on
the 26th of October 2017 (MEC-2017-489). Financial
support is provided by ACIST Medical Systems, Inc.. The
Erasmus Medical Center is totally independent from
ACIST Medical Systems, Inc. regarding the conduct of the
study and the medical treatment of patients and study
subjects. The authors are solely responsible for the design
and conduct of this study, all study analyses, the drafting
and editing of the paper and its final contents. The study
is in accordance with Good Clinical Practices (GCP),
ISO14155 and with the Declaration of Helsinki (64th
WMA General Assembly, Fortaleza, Brazil, October 2013).
The study is registered at the Dutch trial register:
NTR6711.
Study population
With the assumption that post PCI FFR will be b0.90 in
45% of the patients, an estimated number of 640 patients
will be enrolled in order to be able to randomize 290
patients. Detailed in- and exclusion criteria are depicted
in Table I. Each patient must sign and date the approved
informed consent form after the study has been
thoroughly explained.
Study endpoints. The primary endpoint will be
assessed at 1-year follow-up and is defined as target vessel
failure, a composite of cardiac death, target vessel Q-wave
or non-Q wave MI and clinically driven TVR.
Secondary endpoints consist of the individual compo-
nents of the primary endpoint at 6 months, 1, 2 and 3
years, along with other clinical endpoints: all-cause death,
any coronary revascularization, non-fatal MI, stent throm-
bosis (according the ARC criteria11), stroke, periproce-
dural complications and acute kidney injury. Procedural
characteristics such as contrast medium usage, number of
stents, total stent length and procedural time will be
compared between groups. Additionally, correlations
between changes in post procedural FFR and Pd/Pa and
luminal dimensions on IVUS due to potential optimization
will be assessed. Table II depicts both primary and
secondary endpoints.
Finally, operator PCI strategy will be assessed at
multiple time points.Blinding and randomization
Patient randomization will be initiated through a web-
based application (ALEA, Formvision, Utrecht, The
Netherlands). In order to prevent a disturbed allocation
between treatment arms, a block randomization will be
used, varying between four and six in size. Subjects will
be blinded to the post procedural FFR and subsequent
treatment allocation. In order to monitor the level of
blinding, the perceived treatment allocation will be
inquired at the 1 year clinical follow-up visit. Further-
more, the procedure report will not contain any details
Figure 1
Study flow chart including the operator strategy questionnaire. The first two rhombuses contain the operator questions. The third rhombus is not
asked but filled in according to the additional intervention. Nine possible answers are provided. FFR is fractional flow reserve, HD-IVUS is high
definition intravascular ultrasound and PCI is percutaneous coronary intervention.
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allocation. More specifically, no information will be
provided on the measured vessel, post PCI FFR value
and potential randomization allocation in the procedure
report or discharge letter. Event adjudication at the set
time points of 6 months, 1, 2 and 3 years will be
performed by an independent critical event committee,
not aware of the patients’ specific FFR values and/or
randomization allocation. Patients will be unblinded at
the last follow-up moment (3 years).
Investigational products. Post PCI FFR will be
assessed using the Navvus® monorail microcatheter
(ACIST Medical Systems, Inc., Eden Prairie, MN) ad-
vanced over the previously used coronary guidewire.
This monorail microcatheter precludes the need to
advance a separate pressure wire along the treatmentsegment which will simplify and speed-up post PCI FFR
measurements.12
Additional imaging in the intervention group will be
performed using the multi frequency (40–60 MHz)
Kodama® HD-IVUS catheter (ACIST Medical Systems,
Inc., Eden Prairie, MN). Both devices are CE marked and
are currently used in regular clinical practice.
Study procedures
Routine care. Procedures will be performed according to
standard clinical practice: angiography guided PCI and
stenting with the use of periprocedural imaging, (either
IVUS or OCT) and/or pre-procedural functional assess-
ment (either iFR or FFR) left at the discretion of the
operator.13 Angiographic success was defined as residual
stenosis b30% by visual analysis in the presence of TIMI 3
grade flow. Procedural success will be identified as
Table I. In- and exclusion criteria.
Inclusion criteria
- Age ≥18
- Stable- or unstable angina or Non-ST segment elevation myocardial
infarction
- Target lesion stenosis ≥50% by visual estimation or QCA successfully
treated by PCI and stenting
- Written informed consent
- The patient agrees to the follow-up
Exclusion criteria:
- Patients with ST-elevation myocardial infarction within the last 72
hours.
- Target vessel distal reference diameter b 2.25 mm
- Cardiogenic shock or severe hemodynamic instability
- Unsuccessful stenting
- PCI without stenting
- Inability to perform post procedure FFR
- The patient has other medical illnesses (i.e., cancer) that may cause the
patient to be non-compliant with the protocol, confound the data
interpretation or are associated with limited life expectancy (i.e., less
than 1 year)
QCA is quantitative coronary angiography, FFR is fractional flow reserve, PCI is
percutaneous coronary intervention.
Table II. Primary and secondary endpoints of the FFR-REACT
trial.
rimary endpoints
Target vessel failure⁎
econdary endpoints
hospital
- Procedural characteristics e.g. contrast medium usage, no. of stents,
total stent length and procedural time
- Major access site bleeding
- Periprocedural MI
- Acute kidney injury
- Periprocedural complications
- Change in post-procedural FFR after optimization therapy
- Change in post-procedural Pd/Pa and FFR after optimization therapy
- Correlation of the IVUS parameters and proximal VS stent VS distal FFR
drop in categories of 0.05.
- Correlation of FFR segmental drop and minimum luminal area on IVUS
and 3D QCA
- Correlation of Pd/Pa and FFR, both dependent and independent of
IVUS findings
- Operators PCI strategy change dependent on the information received
from either FFR or IVUS
months and longer follow-up
- The individual components of the primary endpoint (cardiac death,
target vessel MI, target vessel revascularization)
- All-cause mortality
- Cardiovascular mortality
- Prehospitalization for heart failure
- Target lesion revascularization
- Any coronary revascularization
- Non-fatal myocardial infarction
- Stent thrombosis
- Periprocedural MI
- Stroke
- Kidney injury
- Correlation of Pd/Pa, FFR and the primary endpoints components
A composite of cardiac death, target-vessel myocardial infarction and clinically
riven TVR at 1 year. MI is myocardial infarction, FFR is fractional flow reserve, QCA is
uantitative coronary angiography, PCI is percutaneous coronary intervention and
US is intravascular ultrasound.
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MI. Dual antiplatelet therapy (including aspirin and a
P2Y12 inhibitor) will be prescribed for at least 6 months
to all patients consisting of clopidogrel in case of stable
angina, or prasugrel/ticagrelor for at least 12 months in
case of an acute coronary syndrome.14
Study measurements and interventions, if applicable,
will only be performed after confirmation of angiograph-
ic success of the PCI and after administration of
intracoronary nitrates.
Post procedural indices: Pd/Pa and FFR
Pd/Pa is defined as a ratio, where Pd is the distal
coronary pressure derived from the tip of the Navvus®
catheter and Pa stands for proximal coronary pressure
(measured at the tip of the guiding system). The two
values are recorded simultaneously during resting condi-
tions. FFR is defined as mean distal coronary artery
pressure divided by mean aortic pressure during maxi-
mum hyperemia achieved by continuous intravenous
infusion of adenosine at a rate of 140 μg/kg/min through
an antecubital vein.
Both indices will be measured approximately 20 mm
from the most distal stent edge. A pullback will be
performed to obtain pressure gradients on the distal and
proximal stent edges. Drift will be checked at the end of
each pullback. Measurements with a drift value above
0.02 will be repeated a second time.15 All vessels with a
drift value above 0.05 during the second attempt will be
excluded from the study. All pressure tracing will be
stored in a dedicated database for off-line analyses. All
tracings will be analyzed for ventricularization, dampen-
ing and drift by our academic corelab.P
S
In
6
⁎
d
q
IVIntravascular ultrasound (Intervention Group)
IVUS-directed FFR optimization will be guided by an
automated pullback with a 40–60 MHz HD-IVUS catheter
at a speed of 2.5 mm/sec (24 frames/mm) starting
approximately 20 mm distal from the most distal stent
edge. Images will be analyzed online in order to identify
potential reasons for the low post-procedural FFR.
Treatment of potential anomalies will be performed
through a guidance protocol initiated in order to
standardize potential further treatment (Table III) and
will be based on the patient's characteristics, angiograph-
ic anatomy, distal and interval Pd/Pa and FFR and luminal
IVUS dimensions. Final resting Pd/Pa and FFR will be
measured at the end of the procedure if additional
treatment was performed along with an IVUS pullback
assessing the final treatment result.
All IVUS pullbacks will be analyzed offline using QCU-
CMS (Leiden University MC, LKEB, Division of Image
Processing, version 4.69). Offline analysis will be
performed by three independent IVUS experts within
our academic corelab. All IVUS pullback will be divided in
Table III. stepwise protocol after high definition IVUS.
Malapposition
- When malapposition is present in more than 1 frame post dilatation
with a balloon ≥0.25 mm larger than the stent balloon is recommended.
Malapposition due to a non-symmetrical vessel should not be
additionally dilated.
Edge dissection
- Additional stenting is recommended in case a distal edge dissection of
more than 90 degrees is encountered. In case of a proximal edge
dissection additional stenting is left at the discretion of the operator.
Underexpansion
- Underexpansion can be measured with the help of a simple calculating
tool, based on the MUSIC criteria.16 This will be done ad hoc. When the
criteria of underexpansion are met, additional dilatation should be
performed preferably by using a non-compliant balloon with a
diameter ≥ 0.25 mm larger than the largest balloon used.
Residual lesion.17-21
- Measure reference vessel diameter (RVD) distally of the potential
residual lesion. A residual lesion is present in case:
○ RVD is 2,5–3,0 mm and lesion MLA is b2,5 mm2
○ RVD is 3,0–3,5 mm and lesion MLA is b3,0 mm2
○ RVD is N3,5 mm and lesion MLA is b3,5 mm2
○ In case left main lesion: if MLA is b6.0 mm2.
- Stent size for additional treatment should be based on lesion length
and RVD.
To ensure a homogenous treatment approach post IVUS imaging of the treated
segment the following guidelines have been designed.
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5 mm) and a proximal segment. The luminal dimensions
for all segments will be separately analyzed, including,
but not limited to, minimal lumen area, minimal lumen
diameter, minimal stent area, mean lumen diameter,
mean lumen diameter and maximum plaque burden.
Additionally, malapposition, stent edge dissections,
underexpansion and residual lesion will be scored
according to Table III.
Conservative treatment (Control Group)
No further treatment or IVUS assessment will be
performed. Procedures will be concluded based on the
confirmation of angiographic success according to
routine clinical practice.
Operator strategy. Operator strategy will be assessed
at 3 time points during the procedure based on the
available information at that stage: following angiography,
following first post-PCI FFR in patients with a FFR b0.90,
and following HD-IVUS in subjects who are randomized to
the IVUS-directed FFR optimization. In the first question,
the operator will be asked what he/she would do in the
hypothetical case the FFR would fall below 0.90. Possible
answers are: 1) place additional proximal stent 2) place
additional distal stent 3) place additional stent proximal and
distal 4) post dilatate stent 5) both post dilatate stent and
additional proximal stent 6) both post dilatate stent and
additional distal stent 7) both post dilatate stent and
additional proximal and distal stent 8) perform intravascu-
lar imaging 9) no additional treatment. A similar question
will be asked directly after the first FFR measurement inwhich the answer may be guided by the information
provided by the initial post PCI Pd/Pa and FFR (pullback)
analyses. The latter two answers will be compared to the
actual treatment strategy based on the IVUS pullback
(Figure 1). The operator strategy questions were added
with the intent to further assess how the use of post PCI
FFR and IVUS impact treatment strategies intended to
improve PCI results.
Follow-up at 6 months, 1, 2 and 3 years follow-up
All patients will be contacted by letter and/or telephone
contact at 6, 24 and 36 months. Before patient contact,
survival status will be ascertained by an automated civil
registry check. A clinical follow-up with ECG will be
scheduled at 12 months. All possible clinical outcomes,
including all-cause mortality, cardiac mortality, myocar-
dial infarction (MI), target lesion revascularization (TLR)
and TVR, any revascularization, stent thrombosis, stroke
and bleeding. Additional information will be retrieved in
case of event triggers from local electronic medical
records, referring physicians and general practitioner.
Data management and monitoring
Registry of specific endpoints and other details will be
managed through OpenClinica, an electronic, online,
case report form (CRF) application. Follow-up contacts
will be performed by physicians or study nurses not
involved in the index procedure and blinded to the final
FFR and assigned treatment arm. All data will be
anonymized and handled confidentially. The key to the
de-anonymization will be safeguarded by the principal
investigator.
Event adjudication will be performed by an indepen-
dent Clinical Events Committee (CEC) unaware of the
post PCI FFR and assigned treatment arm. Specific
information in the PCI report on the treatment strategy
will be masked when submitting documents to the CEC.
Monitoring will verify that the rights and well-being of
the patients are protected, the trial is conducted
according to GCP and ISO14155, and that the protocol
is followed. The trial specific monitoring program is
based on the guidelines for on-site monitoring in
relationship to the estimated risk of the study (Erasmus
MC version 15 November 2012). According to these
guidelines a negligible risk-monitoring program was set
up for the trial.
Statistical considerations
Statistical analysis of endpoints. Categorical variables will be
expressed as percentages and counts. Differences in
categorical variables between randomly allocated treat-
ment groups will be evaluated by applying chi-square
tests or Fisher's exact tests. Continuous variables will be
described as mean ± one standard deviation, or as
median and interquartile range, accordingly. Shapiro–
Wilk tests will be applied to evaluate normality of
continuous variables. Differences in continuous variables
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be evaluated by applying Student's t-tests or Mann–
Whitney tests. Parametric correlations will be assessed
using the Pearson correlation coefficient while the
Spearman's rank correlation coefficient is used if the
correlation is non-parametric.
The operator strategy questionnaire will be evaluated
using the McNemar's test.
Differences between the groups, both randomized and
non-randomized, will be measured using the log-rank
tests to evaluate differences in event-free survival. A
univariate Cox proportional hazard regression will be
used to quantify the relation between randomly allocated
treatment arms and the incidence of clinical outcomes.
In order to provide adjusted hazard ratios (HR), a
multivariate Cox regression will be used, with adjust-
ment for age, sex and (as far as allowed given the number
of endpoint events) other confounders, possibly includ-
ing stent size, previous coronary artery intervention,
previous MI, multivessel disease, a history of CABG,
dyslipidemia, hypertension, smoking, diabetes mellitus
and renal function. Competing risks are taken into
account for the analysis. Both primary and secondary
study parameters are depicted in Table II.
All tests will be 2-tailed, and a p-value of b0.05 will be
considered statistically significant. The secondary out-
comes are hypothesis generating and therefore no
adjustment for multiple testing will be made. We will
report estimates of population parameters together with
their 95% confidence interval.
Sample size calculation. A recent meta-analysis showed that
the incidence of MACE (heterogeneous definitions used)
in patients with post PCI FFR b0.90 was 21.4% versus 5%
in patients with post PCI FFR ≥ 0.90.4 The average
incidence of MACE in the latter study was 11%. The
average incidence of MACE (comprised of cardiac death,
any MI and TVR) at 1-year post PCI at the Erasmus MC is
10%. When these data are extrapolated, in the Erasmus
MC patients with an FFR b0.90 will have an estimated
MACE incidence of 19%. The MACE incidence of the
patients who will be randomized to optimal care with
IVUS is estimated at 7.5%: the average of the incidence at
the EMC and the 5% that was found in the meta-analysis.
In summary, to determine the sample size we made the
following assumptions/choices:
- Incidence of the study endpoint in those randomized
to control/standard care: 19%
- Incidence of the study endpoint in those randomized
to IVUS-directed stent placement: 7.5%
- type I error, two-sided: 0.05.
- type II error: 0.2 (i.e. power 80%)
- Allocation ratio N2/N1 = 1.
Then a sample size of 272 is required, 136 patients per
treatment arm. The sample size should be enlarged by an
additional 2–5% due to possible technical failures, lost tofollow-up or unsuitable FFR or IVUS acquisition. Finally
290 patients will be randomized.
Based on results of the FFR-SEARCH registry, 45% of the
patients will have a post-procedural FFR b0.90.10 This
implies that a total of approximately 640 patients need to be
enrolled in order find 290patientswith a post PCI FFRb0.90.
Potential issues of concern
The use of FFR and IVUS in daily clinical practice has
been shown to be safe with a low risk of complications. In
the FFR SEARCH study, focusing on the predictive value of
post-procedural FFR in almost 1000 patients, no complica-
tions due to the microcatheter were observed, while in
only 2 patients a severe response to the intravenous
adenosine occurred.10 In a study by van der Sijde et al in
which the risk of periprocedural complications due to the
use of IVUS was assessed in 2476 procedures, 12
complications (0.5%) occurred.22 All of these were self-
limiting after retrieval of the imaging catheter and nomajor
adverse events due to the use of IVUS were found.
Furthermore, limited evidence is available at the moment
on the homogeneity of post PCI FFR values in patients
presenting with stable angina as compared to patients with
unstable angina or non-ST elevation MI. Additionally, pre
PCI FFR assessment using the Navvus microcatheter has
proven to significantly overestimated the stenosis severity
as compared to pressure wire based FFR measure-
ments.23,24 However, this difference was mainly driven
by a larger delta in vesselswith a small minimal luminal area
pre procedure. It is currently unknown if post PCI FFR
assessment with the latter two methods will exemplify the
same variance and direct extrapolation of the current study
to pressure wire based post PCI FFR assessment and
optimization is therefore not possible.
The sample size calculation presented the current study
is based on a meta-analysis which included a heteroge-
neous cohort of studies with several outdated registries.4
The latter might result in an overestimation of the event
rates and thus under-power the study design. Cumulative
incidences are expected to diverge between the treatment
and control group at longer follow-up if the luminal
dimension and FFR can be increased, ensuring a hypothet-
ical under-powered study at one year would be sufficiently
powered at two or three years follow-up.4,5,25,26
Study status and timeline
The FFR REACT trial is actively enrolling patients since
October 31st, 2017 and has reached the milestone of
enrolling 50% of the target population October 2018. At
its current pace the study is expected to complete
enrolment Q4 2019.
Summary
The FFR REACT study is an investigator initiated
prospective, single-center randomized controlled trial
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assess if FFR guided PCI optimization directed by IVUS in
patients with an increased risk for MACE (post-PCI FFR
below 0.90) will decrease target vessel failure at 1 year.
Inclusion started in October 2017 and enrolment is
expected to be complete in Q4 2019.Public disclosure and publication policy
Findings of the study will be submitted for publication
in a peer-reviewed international cardiology journal.
Publication of the data will remain in the hands of the
principal investigator and steering committee. The
Erasmus MC received an unrestricted institutional grant
from ACIST Medical Systems, Inc.References
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